APEX: composition, research context, and what is unproven

A man standing calmly after training on a sunlit stone terrace beside an olive tree

APEX is a named combination of tesamorelin, CJC-1295, ipamorelin, and BPC-157. Three components relate to growth hormone signalling and one comes from tissue repair research. No controlled human study of this combination was identified, so the page separates what is known about each component from what is unknown about the group.

Composition

  • tesamorelin
  • cjc-1295
  • ipamorelin
  • bpc-157

Overview

APEX pairs two growth hormone releasing hormone approaches with a secretagogue and adds a peptide from a different research field entirely. The result is a page that has to hold two separate discussions at once: what growth hormone axis research supports, and what the tissue signalling literature on BPC-157 does and does not establish in humans. Both discussions end in the same place. Component research is not combination research.

Why these are grouped

The stated rationale is coverage of more than one entry point to growth hormone release, with a repair-signalling component added because people asking about recovery often ask about both topics in the same conversation. That is a marketing logic and a mechanistic argument. It is not a demonstrated interaction, and no published study evaluated whether adding BPC-157 changes anything about the growth hormone components.

What each ingredient contributes

tesamorelin

The most extensively studied component here, with an FDA-approved product for one named indication that does not extend to general body composition use.

cjc-1295

A growth hormone releasing hormone analogue studied for a longer signalling profile. Human data are limited to small early studies.

ipamorelin

A secretagogue acting through a different receptor than the releasing hormone analogues, included for pathway breadth rather than proven additive value.

bpc-157

A peptide studied almost entirely in animal models of tissue and gut signalling. Its presence reflects interest in recovery research rather than human evidence.

Combination evidence

  • No randomized trial, controlled study, or trial registration for the APEX combination was identified.
  • There is no published human safety data for these four substances administered together.
  • Claims that the combination supports recovery, body composition, or performance are not supported by any combination study.

Tesamorelin carries real human trial data in a narrow approved indication. CJC-1295 has small early human pharmacology studies. Ipamorelin and BPC-157 rest largely on preclinical work, and BPC-157 in particular has no adequate human trial base. Treat each component page as the evidence source, and treat the combination as untested.

Preclinical rationale

  • Releasing hormone analogues and secretagogues act at different receptors, which is the mechanistic argument for using more than one.
  • BPC-157 appears in rodent models of tendon, muscle, and gastrointestinal signalling that have not been replicated in adequately controlled human studies.

What is not established

  • Whether BPC-157 contributes anything measurable in humans, alone or in this grouping.
  • Whether stacking two growth hormone releasing approaches produces more benefit than one, or simply more IGF-1 response.
  • Safety of the combination over months or years.
  • Any effect on athletic performance, which has not been established for the combination.

Questions to discuss with a physician

  • Does any component here have evidence that applies to my specific situation?
  • What is the argument for four substances rather than one?
  • What laboratory work would you want before and during, and what would make you stop?
  • If I compete in a tested sport, what are the consequences?
  • What non-peptide options should I consider first?

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-15.